NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
|
|
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
|
|
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
|
|
0.800 |
GeneticVariation
|
UNIPROT |
|
|
|
NEUROBLASTOMA, SUSCEPTIBILITY TO
|
|
0.700 |
CausalMutation
|
CLINVAR |
Activating mutations in ALK provide a therapeutic target in neuroblastoma.
|
18923525 |
2008 |
Childhood Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, two human neuroblastoma cell lines harbouring the F1174L</span> mutation were also sensitive to the inhibitor.
|
18923525 |
2008 |
Central neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, two human neuroblastoma cell lines harbouring the F1174L</span> mutation were also sensitive to the inhibitor.
|
18923525 |
2008 |
Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, two human neuroblastoma cell lines harbouring the F1174L</span> mutation were also sensitive to the inhibitor.
|
18923525 |
2008 |
Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activating mutations within the full-length ALK kinase domain, most commonly R1275Q and F1174L, which play a major role in neuroblastoma, were recently identified.
|
20632993 |
2010 |
Central neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activating mutations within the full-length ALK kinase domain, most commonly R1275Q and F1174L, which play a major role in neuroblastoma, were recently identified.
|
20632993 |
2010 |
Childhood Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Activating mutations within the full-length ALK kinase domain, most commonly R1275Q and F1174L, which play a major role in neuroblastoma, were recently identified.
|
20632993 |
2010 |
Neoplasms
|
|
0.080 |
GeneticVariation
|
BEFREE |
ALK mutations occur in equal frequencies across all genomic subtypes, but F1174L mutants are observed in a higher frequency of MYCN-amplified tumors and show increased transforming capacity as compared with the R1275Q mutants.
|
20719933 |
2010 |
Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
|
21030459 |
2010 |
Childhood Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
|
21030459 |
2010 |
Central neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
|
21030459 |
2010 |
Inflammatory Myofibroblastic Tumor
|
|
0.010 |
GeneticVariation
|
BEFREE |
Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.
|
21030459 |
2010 |
NEUROBLASTOMA, SUSCEPTIBILITY TO
|
|
0.700 |
CausalMutation
|
CLINVAR |
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
|
21575866 |
2011 |
NEUROBLASTOMA, SUSCEPTIBILITY TO
|
|
0.700 |
CausalMutation
|
CLINVAR |
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.
|
21838707 |
2011 |
NEUROBLASTOMA, SUSCEPTIBILITY TO
|
|
0.700 |
CausalMutation
|
CLINVAR |
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
|
21948233 |
2011 |
NEUROBLASTOMA, SUSCEPTIBILITY TO
|
|
0.700 |
CausalMutation
|
CLINVAR |
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
|
22072639 |
2011 |
Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most frequent ALK mutations in neuroblastoma cause amino acid substitutions (F1174L and R1275Q) in the intracellular tyrosine kinase domain of the intact ALK receptor.
|
22072639 |
2011 |
Childhood Neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most frequent ALK mutations in neuroblastoma cause amino acid substitutions (F1174L and R1275Q) in the intracellular tyrosine kinase domain of the intact ALK receptor.
|
22072639 |
2011 |
Central neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The most frequent ALK mutations in neuroblastoma cause amino acid substitutions (F1174L and R1275Q) in the intracellular tyrosine kinase domain of the intact ALK receptor.
|
22072639 |
2011 |
Adenocarcinoma of lung (disorder)
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
|
22277784 |
2012 |
Adenocarcinoma of lung (disorder)
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
|
22277784 |
2012 |
Central neuroblastoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we report similar basal patterns of ALK phosphorylation between the neuroblastoma IMR-32 cell line, which expresses only the wild-type receptor (ALK(WT)), and the SH-SY5Y cell line, which exhibits a heterozygous ALK F1174L mutation and expresses both ALK(WT) and ALK(F1174L) receptors.
|
22479414 |
2012 |